A detailed history of Sg Americas Securities, LLC transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Sg Americas Securities, LLC holds 13,189 shares of KALV stock, worth $110,260. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,189
Holding current value
$110,260
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 03, 2024

BUY
$9.46 - $15.39 $124,767 - $202,978
13,189 New
13,189 $153,000
Q1 2024

May 06, 2024

SELL
$11.07 - $16.04 $1.39 Million - $2.02 Million
-125,735 Reduced 91.23%
12,082 $143,000
Q4 2023

Jan 12, 2024

BUY
$7.58 - $12.25 $50,558 - $81,707
6,670 Added 5.09%
137,817 $1.69 Million
Q3 2023

Oct 13, 2023

BUY
$8.95 - $11.35 $87,656 - $111,161
9,794 Added 8.07%
131,147 $1.26 Million
Q2 2023

Jul 10, 2023

BUY
$7.73 - $10.57 $938,058 - $1.28 Million
121,353 New
121,353 $1.09 Million
Q4 2022

Feb 02, 2023

SELL
$4.2 - $14.24 $3,456 - $11,719
-823 Reduced 4.97%
15,734 $106,000
Q3 2022

Oct 31, 2022

SELL
$9.85 - $16.83 $1,319 - $2,255
-134 Reduced 0.8%
16,557 $240,000
Q2 2022

Jul 29, 2022

BUY
$8.16 - $15.1 $136,198 - $252,034
16,691 New
16,691 $164,000
Q1 2022

Apr 29, 2022

SELL
$11.2 - $16.97 $133,907 - $202,893
-11,956 Closed
0 $0
Q4 2021

Feb 07, 2022

SELL
$12.36 - $18.28 $74,679 - $110,447
-6,042 Reduced 33.57%
11,956 $158,000
Q3 2021

Nov 01, 2021

SELL
$17.11 - $24.49 $87,124 - $124,703
-5,092 Reduced 22.05%
17,998 $314,000
Q2 2021

Aug 12, 2021

BUY
$23.12 - $29.91 $15,675 - $20,278
678 Added 3.03%
23,090 $553,000
Q1 2021

May 13, 2021

BUY
$14.69 - $42.57 $248,789 - $720,965
16,936 Added 309.28%
22,412 $576,000
Q4 2020

Feb 04, 2021

BUY
$12.88 - $19.47 $70,530 - $106,617
5,476 New
5,476 $104,000

Others Institutions Holding KALV

About KalVista Pharmaceuticals, Inc.


  • Ticker KALV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,602,000
  • Market Cap $206M
  • Description
  • KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...
More about KALV
Track This Portfolio

Track Sg Americas Securities, LLC Portfolio

Follow Sg Americas Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.